Clinical Trials

We are working with multiple collaborators on studies in several cancer types, with an emphasis on early detection.

We are proud of the clinical evidence, R&D achievements, our FDA’s breakthrough device designation for our pancreatic cancer test panel, and our  history has Bluestar Genomics. Now, as a commercial-stage company, ClearNote Health continues to drive innovation in non-invasive cancer detection, with patient needs at the core of everything we pursue. 

ClearNote Health is currently conducting  several clinical studies at multiple sites. Learn more about study design, patient criteria, and enrollment: 

Tracking Epigenomic Signals To Detect Cancer Early

Learn About Our Platform
ClearNote Health
Privacy Overview

We use cookies, subject to your consent, to analyze the use of our website and to ensure you get the best experience. Third parties with whom we collaborate can also install cookies in order to show you personalized advertisements on other websites. Read our cookie policy for more information.
Read our privacy policy to understand how ClearNote Health handles personal information that we collect through our digital properties that link to this Privacy Policy, including our website and other activities described in the privacy policy.